SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics (Nasdaq: SABS) announced its participation at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, from September 15-19, 2025. The company will deliver five presentations focused on SAB-142, their novel immunotherapy treatment for type 1 diabetes.
The presentations include an INNODIA-hosted symposium and four oral presentations covering various aspects of SAB-142, including its immunomodulation properties, mechanism of action, pharmacokinetic assays, and specimen quality analysis for clinical trials. Key speakers include Dr. Alexandra Kropotova, EVP and Chief Medical Officer, Dr. Christoph Bausch, EVP and Chief Operating Officer, and Dr. Eric Sandhurst, Director of Program Management.
SAB Biotherapeutics (Nasdaq: SABS) ha annunciato la sua partecipazione al 61° Congresso Annuale della European Association for the Study of Diabetes (EASD), che si terrà a Vienna, Austria, dal 15 al 19 settembre 2025. L'azienda presenterà cinque interventi incentrati su SAB-142, la sua nuova immunoterapia per il diabete di tipo 1.
Le presentazioni comprendono un symposium organizzato da INNODIA e quattro comunicazioni orali che affrontano vari aspetti di SAB-142, tra cui le sue proprietà immunomodulatrici, il meccanismo d'azione, i saggi farmacocinetici e l'analisi della qualità dei campioni per gli studi clinici. Tra i relatori principali figurano la Dott.ssa Alexandra Kropotova, EVP e Chief Medical Officer, il Dott. Christoph Bausch, EVP e Chief Operating Officer, e il Dott. Eric Sandhurst, Director of Program Management.
SAB Biotherapeutics (Nasdaq: SABS) anunció su participación en la 61.ª Reunión Anual de la European Association for the Study of Diabetes (EASD), que se celebrará en Viena, Austria, del 15 al 19 de septiembre de 2025. La compañía ofrecerá cinco presentaciones centradas en SAB-142, su nueva inmunoterapia para la diabetes tipo 1.
Las presentaciones incluyen un simposio organizado por INNODIA y cuatro ponencias orales que abarcan distintos aspectos de SAB-142, como sus propiedades inmunomoduladoras, el mecanismo de acción, los ensayos farmacocinéticos y el análisis de la calidad de las muestras para ensayos clínicos. Entre los ponentes principales están la Dra. Alexandra Kropotova, EVP y Chief Medical Officer, el Dr. Christoph Bausch, EVP y Chief Operating Officer, y el Dr. Eric Sandhurst, Director de Program Management.
SAB Biotherapeutics (Nasdaq: SABS)는 2025년 9월 15일부터 19일까지 오스트리아 비엔나에서 열리는 제61회 유럽당뇨병학회(EASD) 연례회의에 참가한다고 발표했습니다. 회사는 제1형 당뇨병 치료를 위한 신규 면역치료제 SAB-142에 관해 다섯 편의 발표를 진행합니다.
발표 내용은 INNODIA 주최 심포지엄과 SAB-142의 면역조절 특성, 작용기전, 약동학 분석법, 임상시험을 위한 검체 품질 분석 등 다양한 주제를 다루는 네 건의 구두 발표로 구성됩니다. 주요 연사로는 Dr. Alexandra Kropotova(EVP 겸 최고의료책임자), Dr. Christoph Bausch(EVP 겸 최고운영책임자), Dr. Eric Sandhurst(프로그램 매니지먼트 이사)가 포함됩니다.
SAB Biotherapeutics (Nasdaq: SABS) a annoncé sa participation à la 61e réunion annuelle de l'European Association for the Study of Diabetes (EASD) qui se tiendra à Vienne, Autriche, du 15 au 19 septembre 2025. La société présentera cinq communications consacrées à SAB-142, sa nouvelle immunothérapie pour le diabète de type 1.
Les interventions comprennent un symposium organisé par INNODIA et quatre présentations orales couvrant divers aspects de SAB-142, notamment ses propriétés immunomodulatrices, son mécanisme d'action, les essais pharmacocinétiques et l'analyse de la qualité des échantillons pour les essais cliniques. Parmi les principaux intervenants figurent la Dr. Alexandra Kropotova, EVP et Chief Medical Officer, le Dr. Christoph Bausch, EVP et Chief Operating Officer, et le Dr. Eric Sandhurst, Director of Program Management.
SAB Biotherapeutics (Nasdaq: SABS) gab seine Teilnahme an der 61. Jahrestagung der European Association for the Study of Diabetes (EASD) bekannt, die vom 15. bis 19. September 2025 in Wien, Österreich, stattfindet. Das Unternehmen wird fünf Präsentationen zu SAB-142 halten, seiner neuen Immuntherapie für Typ-1-Diabetes.
Die Vorträge umfassen ein von INNODIA veranstaltetes Symposium sowie vier mündliche Beiträge, die verschiedene Aspekte von SAB-142 behandeln, darunter immunmodulatorische Eigenschaften, Wirkmechanismus, pharmakokinetische Tests und die Analyse der Probenqualität für klinische Studien. Zu den Hauptreferenten gehören Dr. Alexandra Kropotova, EVP und Chief Medical Officer, Dr. Christoph Bausch, EVP und Chief Operating Officer, sowie Dr. Eric Sandhurst, Director of Program Management.
- None.
- None.
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.
Information on all presentations is below:
INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium
Working to Change the Lives of People Impacted by Type 1 Diabetes Through Unique Disease-Modifying Therapy
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Monday, September 15, 2025 | 16:40 – 20:00 CEST
Location: Lima Hall
EASD Presentations:
Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Behind the Screens: Adventures in T1D Clinical Trials | Presentation 19
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Tuesday, September 16, 2025 | 10:00 – 11:30 CEST
Location: Mumbai Hall
Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: OP 28 “Guardians of the Islet Galaxy: Protect and Replace” | Presentation 163
Presenter: Christoph Bausch, PhD, EVP and Chief Operating Officer
Presentation Date & Time: Thursday, September 18, 2025 | 10:45 – 12:15 CEST
Location: Sofia Hall
Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 391
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMC
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 392
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
About EASD Annual Meeting
The EASD Annual Meeting is the largest diabetes conference in the world, attracting thousands of delegates. The program showcases the latest results from basic and clinical research.
For more information, visit https://www.easd.org/annual-meeting/easd-2025/.
About INNODIA
INNODIA is an international non-profit organization that stemmed from a European-based public-private partnership co-funded by the European Commission’s Innovative Medicines Initiative (IMI-JU Joint Undertaking), The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners. Thanks to this unique private-public interaction, INNODIA has become the largest European Network dedicated to prevent and cure type 1 diabetes and today it is a legal entity that represents the interface between those who want to develop new therapies and those who have the tools and experience to do so.
For more information, visit https://www.innodia.eu/.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.
CONTACTS
Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Inquiries:
SAB BIO
Sheila Carlson
scarlson@sab.bio
FAQ
When and where is SAB Biotherapeutics (SABS) presenting at EASD 2025?
What is SAB-142 and what is it being developed for?
How many presentations will SAB Biotherapeutics deliver at EASD 2025?
Who are the key presenters from SAB Biotherapeutics at EASD 2025?
